National Center for Complementary & Alternative Medicine; Notice of Closed Meetings, 38405-38406 [06-5994]

Download as PDF jlentini on PROD1PC65 with NOTICES Federal Register / Vol. 71, No. 129 / Thursday, July 6, 2006 / Notices Canada and works with other nations and multilateral organizations (e.g., WHO) in combating public health threats, emergencies, and bioterrorism by establishing bilateral and multilateral international arrangements to develop early warning surveillance and response capability for infectious disease outbreaks, including those involving potential bioterrorism agents. OMSPH provides leadership in the activities of the regional and multilateral groups including the Global Health Security Action Group (GHSAG) and the Security and Prosperity Partnership (SPP) and the implementation of the WHO International Health Regulations (IHR), in coordination with the Office of Global Health Affairs. 5. Office of Policy and Strategic Planning (ANE). The Office of Policy and Strategic Planning (OPSP) is headed by a Director and is responsible for policy formulation, analysis, coordination, and evaluation for preparedness, response, and strategic planning. In coordination with other OPHEP and Departmental offices, OPSP analyzes proposed policies, Presidential directives and regulations. OPSP also develops short and long-term policy and strategic objectives for OPHEP, and leads in the development and implementation of an integrated OPHEP approach to policy, strategy, and longterm, planning processes. On behalf of the ASPHEP, OPSP serves as the focal point for HSC/NSC policy coordination activities and represent the ASPHEP, as appropriate, in interagency meetings. The office undertakes studies of preparedness and response issues, identifying gaps in policy, and initiating policy planning and formulation to fill these gaps. OPSP takers the lead on special projects, initiatives, and policy analysis and evaluation as tasked by the ASPHEP. II. Continuation of Policy: Except as inconsistent with this reorganization, all statements of policy and interpretations with respect to the Office of Public Health Emergency Preparedness heretofore issued and in effect prior to the date of this reorganization are continued in full force and effect. III. Delegations of Authority: All delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegation, provided they are consistent with this reorganization. IV. Funds, Personnel and Equipment: Transfer of organizations and functions affected by this reorganization shall be accompanied in each instance by direct VerDate Aug<31>2005 17:01 Jul 05, 2006 Jkt 208001 and support funds, positions, personnel, records, equipment and other resources. Dated: June 27, 2006. Joe Ellis, Assistant Secretary for Administration and Management. [FR Doc. 06–6004 Filed 7–5–06; 8:45 am] 38405 Dated: June 29, 2006. Kathy Skipper, Acting Director, Management Analysis and Services Office , Centers for Disease Control and Prevention. [FR Doc. 06–6035 Filed 7–5–06; 8:45 am] BILLING CODE 4163–18–P BILLING CODE 4150–37–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panels (SEP): HIV III—OPTOut Testing in Emergency Department Settings, Program Announcement (PA) PS06–003 In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting: Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): HIV III—OPTOut Testing in Emergency Department Settings, PA PS06–003. Time and Date: 12 p.m.–1 p.m., July 12, 2006 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to ‘‘HIV III—OPT-Out Testing in Emergency Department Settings,’’ PA PS06–003. Due to programmatic matters, this Federal Register Notice is being published on less than 15 calendar days notice to the public (41 CFR 102–3.150(b)). Contact Person for More Information: Jim Newhall, Ph.D., Scientific Review Administrator, Office of Public Health Research, CDC, 1600 Clifton Road NE, Mailstop D72, Atlanta, GA 30333, Telephone 404.639.4641. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Complementary & Alternative Medicine; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Complementary and Alternative Medicine Special Emphasis Panel, Tools and Technology to Measure Menopausal Symptomotology. Date: July 24, 2006. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Center for Complementary, and Alternative Medicine, NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Laurie Friedman Donze, PhD, Scientific Review Administrator, Office of Scientific Review, National Center for Complementary and Alternative Medicine, NIH, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, 301–402–1030, donzel@mail.nih.gov. Name of Committee: National Center for Complementary and Alternative Medicine Special Emphasis Panel, Tools and Technology to Measure Patient Adherence in CAM Research. Date: July 25, 2006. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Center for Complementary and Alternative Medicine, NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Laurie Friedman Donze, PhD, Scientific Review Administrator, Office of Scientific Review, National Center for Complementary and Alternative Medicine, E:\FR\FM\06JYN1.SGM 06JYN1 38406 Federal Register / Vol. 71, No. 129 / Thursday, July 6, 2006 / Notices NIH, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, 301–402–1030, donzel@mail.nih.gov. Dated: June 28, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–5994 Filed 7–5–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Research Resources; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Center for Research Resources Special Emphasis Panel, June 21, 2006, 2 p.m. to June 21, 2006, 4 p.m., National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Conference Room 1087, Bethesda, MD 20892 which was published in the Federal Register on May 31, 2006, 71 FR 30943. The date of the meeting has been changed to July 18, 2006. The time and location remains the same. The meeting is closed to the public. Dated: June 28, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–5995 Filed 7–5–06; 8:45 am] BILLING CODE 4140–01–M Name of Committee: National Human Genome Research Institute Special Emphasis Panel, Sequencing Technology RFA. Date: July 18–19, 2006. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: The Hotel Rouge, 1315 16th Street, Washington, DC 20036. Contact Person: Ken D. Nakamura, PhD, Scientific Review Administrator, Scientific Review Branch, National Human Genome Research Institute, National Institutes of Health, 5635 Fishers Lane, Suite 4076, MSC 9306, Rockville, MD 20582, 301–402–0838. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Human Genome Research Institute, Special Emphasis Panel, ELSI Public Consultation RFA. Date: July 20, 2006. Time: 1 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: The Watergate, 2650 Virginia Avenue, NW, Washington, DC 20037. Contact Person: Rudy O. Pozzatti, PhD, Scientific Review Administrator, Office of Scientific Review, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, 301 402–0383. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: June 28, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–5993 Filed 7–5–06; 8:45 am] BILLING CODE 4140–01–M National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Human Genome Research Institutes; Notice of Closed Meetings jlentini on PROD1PC65 with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. VerDate Aug<31>2005 19:52 Jul 05, 2006 Jkt 208001 National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Training in Computational Neuroscience: From Biology to Model and Back Again. Date: June 29, 2006. Time: 8:30 a.m. to 5 a.m. Agenda: To review and evaluate grant applications. Place: Ritz-Carlton Hotel, 1700 Tysons Boulevard, McLean, VA 22102. Contact Person: Murat Oz, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Neuroscience Center, Rm. 229, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892, 301–435–1433, moz2@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Member Conflict. Date: June 30, 2006. Time: 2:30 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Gerald L. McLaughlin, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892–8401, 301–402–6626, gm145a@nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Member Conflict. Date: July 18, 2006. Time: 5 p.m. to 7 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Murat Oz, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Neuroscience Center, Rm. 229, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892, 301–435–1433, moz2@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) E:\FR\FM\06JYN1.SGM 06JYN1

Agencies

[Federal Register Volume 71, Number 129 (Thursday, July 6, 2006)]
[Notices]
[Pages 38405-38406]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-5994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Complementary & Alternative Medicine; Notice 
of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2) notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Complementary and 
Alternative Medicine Special Emphasis Panel, Tools and Technology to 
Measure Menopausal Symptomotology.
    Date: July 24, 2006.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Center for Complementary, and Alternative 
Medicine, NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 
20892 (Telephone Conference Call).
    Contact Person: Laurie Friedman Donze, PhD, Scientific Review 
Administrator, Office of Scientific Review, National Center for 
Complementary and Alternative Medicine, NIH, 6707 Democracy Blvd., 
Suite 401, Bethesda, MD 20892, 301-402-1030, donzel@mail.nih.gov.

    Name of Committee: National Center for Complementary and 
Alternative Medicine Special Emphasis Panel, Tools and Technology to 
Measure Patient Adherence in CAM Research.
    Date: July 25, 2006.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Center for Complementary and Alternative 
Medicine, NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 
20892 (Telephone Conference Call).
    Contact Person: Laurie Friedman Donze, PhD, Scientific Review 
Administrator, Office of Scientific Review, National Center for 
Complementary and Alternative Medicine,

[[Page 38406]]

NIH, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, 301-402-
1030, donzel@mail.nih.gov.

    Dated: June 28, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-5994 Filed 7-5-06; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.